Drug Discovery & Development
Researchers call for rapid drug repurposing to fight COVID-19
Filling the therapeutic gap for coronavirus treatments with existing drugs approved for other uses could greatly benefit patients around the world. Researchers from the University of Kentucky urged the scientific community to quickly identify drugs that may be repurposed in the fight against COVID-19 in an opinion piece published May 8 in Science. Read More
Genomic tools help researchers understand how SARS-CoV-2 is evolving
A new study has identified nearly 200 recurrent genetic mutations in the SARS-CoV-2 virus, according to research published as a preproof in Infection, Genetics and Evolution on May 5. The findings could offer clues to how the virus is adapting and evolving in humans and lead to optimal drug and vaccine targets. Read More
Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating the development of an effective vaccine to SARS-CoV-2 infection. The results of the study were published in Immunity on May 3. Read More
Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents the SARS-CoV-2 virus from infecting cultured cells. Authored by a team of researchers from Utrecht University, Erasmus Medical Center, and Harbour BioMed, the report was published in Nature Communications on May 4. Read More
Cytokine storm may cause T-cell exhaustion in COVID-19 cases
Cytokine storms may impact the severity of COVID-19 cases by lowering T-cell populations, according to a study published in Frontiers in Immunology on May 1. Read More
COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the novel coronavirus. In a new article, Ivan Gandayuwana of Strategic Directions International examines the multiple impacts COVID-19 is having on pharma. Read More
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene therapy, according to a new review article published April 24 in Frontiers in Microbiology. Read More
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19 vaccine candidates, five of which have already entered clinical trials. Read More
Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly reduce the discovery time for possible new antibody-based therapies. The approach, published in Nature Communications on April 14, shows how protein fragments can be screened for susceptibility to aggregation in early drug discovery. Read More
Scientists explore SARS-CoV-2 main protease as a drug target
A team of researchers report the structure of the main protease of the novel coronavirus and have identified several drugs that show promise in combating the virus, according to an April 9 article published in Nature. Read More
Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter